126 related articles for article (PubMed ID: 38450878)
1. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
Ezekowitz J; Alemayehu W; Edelmann F; Ponikowski P; Lam CSP; O'Connor CM; Butler J; Corda S; McMullan CJ; Westerhout CM; Voors AA; Mentz RJ; Armstrong PW;
Eur J Heart Fail; 2024 Mar; 26(3):628-637. PubMed ID: 38450878
[TBL] [Abstract][Full Text] [Related]
2. Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial.
Lam CSP; Giczewska A; Sliwa K; Edelmann F; Refsgaard J; Bocchi E; Ezekowitz JA; Hernandez AF; O'Connor CM; Roessig L; Patel MJ; Pieske B; Anstrom KJ; Armstrong PW;
JAMA Cardiol; 2021 Jun; 6(6):706-712. PubMed ID: 33185650
[TBL] [Abstract][Full Text] [Related]
3. Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction.
Coiro S; Girerd N; McMurray JJV; Pitt B; Swedberg K; van Veldhuisen DJ; Lamiral Z; Rossignol P; Zannad F
Clin Res Cardiol; 2021 Aug; 110(8):1308-1320. PubMed ID: 33956209
[TBL] [Abstract][Full Text] [Related]
4. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
5. Loop diuretic down-titration at discharge in patients hospitalized for acute heart failure.
Croset F; Llàcer P; Núñez J; Campos J; García M; Pérez A; Fernández C; Fabregate M; López G; Tello S; Fernández JM; Ruiz R; Manzano L
ESC Heart Fail; 2024 Jun; 11(3):1739-1747. PubMed ID: 38454739
[TBL] [Abstract][Full Text] [Related]
6. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Chatur S; Vaduganathan M; Claggett B; Vardeny O; Desai AS; Jhund PS; de Boer RA; Lam CSP; Kosiborod MN; Shah SJ; Martinez F; Inzucchi SE; Hernandez AF; Haddad T; Mitter SS; Miao ZM; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
Eur Heart J; 2023 Aug; 44(31):2930-2943. PubMed ID: 37220093
[TBL] [Abstract][Full Text] [Related]
7. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction.
Damman K; Kjekshus J; Wikstrand J; Cleland JG; Komajda M; Wedel H; Waagstein F; McMurray JJ
Eur J Heart Fail; 2016 Mar; 18(3):328-36. PubMed ID: 26693947
[TBL] [Abstract][Full Text] [Related]
8. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial.
Vardeny O; Claggett B; Kachadourian J; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
Eur J Heart Fail; 2019 Mar; 21(3):337-341. PubMed ID: 30741494
[TBL] [Abstract][Full Text] [Related]
9. Loop diuretic down-titration in stable chronic heart failure is often achievable, especially when urinary chloride concentration is low.
Verbrugge FH; Martens P; Boonen L; Nijst P; Verhaert D; Noyens P; De Vusser P; Dupont M; Tang WHW; Mullens W
Acta Cardiol; 2018 Aug; 73(4):335-341. PubMed ID: 28971753
[TBL] [Abstract][Full Text] [Related]
10. Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit.
Buckley LF; Carter DM; Matta L; Cheng JW; Stevens C; Belenkiy RM; Burpee LJ; Young MA; Weiffenbach CS; Smallwood JA; Stevenson LW; Desai AS
JACC Heart Fail; 2016 Jan; 4(1):1-8. PubMed ID: 26656139
[TBL] [Abstract][Full Text] [Related]
11. Acute Diuretic-Sparing Effects of Sacubitril-Valsartan: Staying in the Loop.
Orvin NJ; Beavers JC; Russell SD
J Pharm Pract; 2022 Dec; 35(6):859-863. PubMed ID: 33882753
[TBL] [Abstract][Full Text] [Related]
12. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.
Ter Maaten JM; Martens P; Damman K; Dickstein K; Ponikowski P; Lang CC; Ng LL; Anker SD; Samani NJ; Filippatos G; Cleland JG; Zannad F; Hillege HL; van Veldhuisen DJ; Metra M; Voors AA; Mullens W
Clin Res Cardiol; 2020 Aug; 109(8):1048-1059. PubMed ID: 32002631
[TBL] [Abstract][Full Text] [Related]
13. Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON-HF trial.
Chatur S; Claggett BL; Vardeny O; Jering K; Desai AS; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
Eur J Heart Fail; 2023 Jan; 25(1):87-94. PubMed ID: 36181769
[TBL] [Abstract][Full Text] [Related]
14. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
[TBL] [Abstract][Full Text] [Related]
15. Changes in Loop Diuretic Dose and Outcome After Cardiac Resynchronization Therapy in Patients With Heart Failure and Reduced Left Ventricular Ejection Fractions.
Martens P; Verbrugge FH; Nijst P; Dupont M; Mullens W
Am J Cardiol; 2017 Jul; 120(2):267-273. PubMed ID: 28532770
[TBL] [Abstract][Full Text] [Related]
16. Outcomes Associated With a Strategy of Adjuvant Metolazone or High-Dose Loop Diuretics in Acute Decompensated Heart Failure: A Propensity Analysis.
Brisco-Bacik MA; Ter Maaten JM; Houser SR; Vedage NA; Rao V; Ahmad T; Wilson FP; Testani JM
J Am Heart Assoc; 2018 Sep; 7(18):e009149. PubMed ID: 30371181
[TBL] [Abstract][Full Text] [Related]
17. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
18. Short-term diuretic withdrawal in stable outpatients with mild heart failure and no fluid retention receiving optimal therapy: a double-blind, multicentre, randomized trial.
Rohde LE; Rover MM; Figueiredo Neto JA; Danzmann LC; Bertoldi EG; Simões MV; Silvestre OM; Ribeiro ALP; Moura LZ; Beck-da-Silva L; Prado D; Sant'Anna RT; Bridi LH; Zimerman A; Raupp da Rosa P; Biolo A
Eur Heart J; 2019 Nov; 40(44):3605-3612. PubMed ID: 31424503
[TBL] [Abstract][Full Text] [Related]
19. Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.
Mentz RJ; Stebbins A; Butler J; Chiang CE; Ezekowitz JA; Hernandez AF; Hilkert R; Lam CSP; McDonald K; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Sweitzer NK; Voors AA; Anstrom KJ; Armstrong PW;
JACC Heart Fail; 2024 May; 12(5):839-846. PubMed ID: 38363272
[TBL] [Abstract][Full Text] [Related]
20. Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF.
DeVore AD; Hasselblad V; Mentz RJ; O'Connor CM; Armstrong PW; McMurray JJ; Ezekowitz JA; Tang WH; Starling RC; Voors AA; Califf RM; Hernandez AF
Eur J Heart Fail; 2015 Mar; 17(3):340-6. PubMed ID: 25619549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
